Frank Joseph Brescia, MD, MA in Mount ...

Dr. Frank J. Brescia

Claim this profile

Medical University of South Carolina

Studies Breast Cancer
Studies Breast cancer
8 reported clinical trials
21 drugs studied

Area of expertise

1

Breast Cancer

Frank J. Brescia has run 8 trials for Breast Cancer. Some of their research focus areas include:

HER2 positive
ER positive
Stage IV
2

Breast Cancer

Frank J. Brescia has run 7 trials for Breast cancer. Some of their research focus areas include:

HER2 positive
ER positive
Stage IV

Affiliated Hospitals

Image of trial facility.

Medical University Of South Carolina

Image of trial facility.

Tidelands Georgetown Memorial Hospital

Clinical Trials Frank J. Brescia is currently running

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. The usual approach for patients with early-stage TNBC who receive preoperative chemotherapy plus pembrolizumab is to continue to receive pembrolizumab for up to 27 weeks after surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation is as good as receiving pembrolizumab for 27 weeks after surgery in triple-negative breast cancer patients who achieved a pathologic complete response after preoperative treatment with chemotherapy and pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

More about Frank J. Brescia

Clinical Trial Related

10 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Frank J. Brescia has experience with

  • Paclitaxel
  • Docetaxel
  • Positron Emission Tomography
  • Computed Tomography
  • Fludeoxyglucose F-18
  • Carvedilol

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Frank J. Brescia specialize in?

Is Frank J. Brescia currently recruiting for clinical trials?

Are there any treatments that Frank J. Brescia has studied deeply?

What is the best way to schedule an appointment with Frank J. Brescia?

What is the office address of Frank J. Brescia?

Is there any support for travel costs?